Skip to main content
Top
Published in: Drugs & Aging 4/2005

01-04-2005 | Original Research Article

Cognitive Impairment as Determinant for Sub-Optimal Control of Oral Anticoagulation Treatment in Elderly Patients with Atrial Fibrillation

Authors: Bob A. J. van Deelen, Dr Patricia M. L. A. van den Bemt, Toine C. G. Egberts, Annelies van’t Hoff, Huub A. A. M. Maas

Published in: Drugs & Aging | Issue 4/2005

Login to get access

Abstract

Background and objective

Atrial fibrillation is an indication for oral anticoagulation treatment. Maintaining the International Normalized Ratio (INR) within the therapeutic range minimises thromboembolic and bleeding complications. We have investigated whether cognitive capacity affects control of anticoagulation in elderly patients with atrial fibrillation.

Patients and methods

A retrospective study was conducted to investigate the association between cognitive impairment and control of anticoagulation. Patients ≥70 years of age with atrial fibrillation using acenocoumarol (nicoumalone) as anticoagulant were included. All patients were monitored by the Anticoagulation Clinic in the Midden-Brabant region in the Netherlands. The cognitive function of all patients was assessed using the Mini-Mental State Examination (MMSE) on the index date. INR values were obtained from the year preceding the index date. Patients with an MMSE score <23 were defined as cognitively impaired. The primary outcome of the study was the incidence of an INR value within the therapeutic range of 2.0–3.4 during ≤70% of treatment time in the year prior to the cognitive function assessment. The secondary endpoint was the number of patients with an INR <2.0 or ≥6.0 at least once during this year. Logistic regression analysis was used to evaluate the association between cognitive function and control of anticoagulation.

Results

A total of 152 patients were included in the study. An MMSE score <23 was associated with an inadequate INR control (odds ratio [OR] 2.77; 95% CI 1.13, 6.74). After correction for hospital admission and change of possibly interacting medication (both also associated with inadequate INR control), this association remained statistically significant. Significantly more patients with an MMSE score <23 had one or more INR values of six or higher (OR 3.06; 95% CI 1.14, 8.18).

Conclusion

In elderly people with atrial fibrillation using oral anticoagulation, an MMSE score <23 is independently associated with an inadequate INR control, mainly because of an increased number of supratherapeutic INR values. This finding should be taken into account when making decisions about use of oral anticoagulants in the elderly.
Literature
1.
go back to reference Wyse DG. Some recent randomized clinical trials in the management of atrial fibrillation. J Interv Card Electrophysiol 2003; 9(2): 223–8PubMedCrossRef Wyse DG. Some recent randomized clinical trials in the management of atrial fibrillation. J Interv Card Electrophysiol 2003; 9(2): 223–8PubMedCrossRef
2.
go back to reference Taylor FC, Cohen H, Ebrahim S. Systemic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001; 322: 321–6PubMedCrossRef Taylor FC, Cohen H, Ebrahim S. Systemic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001; 322: 321–6PubMedCrossRef
3.
go back to reference Dhond AJ, Michelena HI, Ezekowitz MD. Anticoagulation in the elderly. Am J Geriatr Cardiol 2003; 12: 243–50PubMedCrossRef Dhond AJ, Michelena HI, Ezekowitz MD. Anticoagulation in the elderly. Am J Geriatr Cardiol 2003; 12: 243–50PubMedCrossRef
4.
go back to reference AGS Clinical Practices Committee. American Geriatric Society. The use of oral anticoagulants (warfarin) in older people. J Am Geriatr Soc 2000; 48: 224–7 AGS Clinical Practices Committee. American Geriatric Society. The use of oral anticoagulants (warfarin) in older people. J Am Geriatr Soc 2000; 48: 224–7
5.
go back to reference Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019–26PubMedCrossRef Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019–26PubMedCrossRef
6.
go back to reference Palareti G, Hirsh J, Legnani C, et al. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med 2000; 160: 470–8PubMedCrossRef Palareti G, Hirsh J, Legnani C, et al. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med 2000; 160: 470–8PubMedCrossRef
7.
go back to reference Sebastian JL, Tresch DD. Use of oral anticoagulants in older patients. Drugs Aging 2000; 16: 409–35PubMedCrossRef Sebastian JL, Tresch DD. Use of oral anticoagulants in older patients. Drugs Aging 2000; 16: 409–35PubMedCrossRef
8.
go back to reference Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370–5PubMedCrossRef Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370–5PubMedCrossRef
9.
go back to reference Ott A, Breteler MM, de Bruyne MC, et al. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997; 28: 316–21 Ott A, Breteler MM, de Bruyne MC, et al. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997; 28: 316–21
10.
go back to reference Sabatini T, Frisoni GB, Barbisoni P, et al. Atrial fibrillation and cognitive disorders in older people. J Am Geriatr Soc 2000; 48: 387–90PubMed Sabatini T, Frisoni GB, Barbisoni P, et al. Atrial fibrillation and cognitive disorders in older people. J Am Geriatr Soc 2000; 48: 387–90PubMed
11.
go back to reference Geroldi C, Ferrucci L, Bandinelli S, et al. Mild cognitive deterioration with subcortical features: prevalence, clinical characteristics, and association with cardiovascular risk factors in community-dwelling older persons (The InCHIANTI Study). J Am Geriatr Soc 2003; 51(8): 1064–71PubMedCrossRef Geroldi C, Ferrucci L, Bandinelli S, et al. Mild cognitive deterioration with subcortical features: prevalence, clinical characteristics, and association with cardiovascular risk factors in community-dwelling older persons (The InCHIANTI Study). J Am Geriatr Soc 2003; 51(8): 1064–71PubMedCrossRef
12.
go back to reference van den Besselaar AM, van der Meer FJ, Gerrits-Drabbe CW. Therapeutic control of oral anticoagulant treatment in The Netherlands. Am J Clin Pathol 1988; 90: 685–90PubMed van den Besselaar AM, van der Meer FJ, Gerrits-Drabbe CW. Therapeutic control of oral anticoagulant treatment in The Netherlands. Am J Clin Pathol 1988; 90: 685–90PubMed
13.
go back to reference Visser LE, Penning-van Beest FJ, Kasbergen AA, et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002; 88: 705–10PubMed Visser LE, Penning-van Beest FJ, Kasbergen AA, et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002; 88: 705–10PubMed
14.
go back to reference Penning-van Beest FJ, van Meegen E, Rosendaal FR, et al. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther 2001; 69: 451–7PubMedCrossRef Penning-van Beest FJ, van Meegen E, Rosendaal FR, et al. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther 2001; 69: 451–7PubMedCrossRef
15.
go back to reference Hylek EM. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin Geriatr Med 2001; 17: 1–13 Hylek EM. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin Geriatr Med 2001; 17: 1–13
16.
go back to reference Lackie CL, Garbarino KA, Pruetz JA. Warfarin therapy for atrial fibrillation in the elderly. Ann Pharmacother 2002; 36: 200–4PubMedCrossRef Lackie CL, Garbarino KA, Pruetz JA. Warfarin therapy for atrial fibrillation in the elderly. Ann Pharmacother 2002; 36: 200–4PubMedCrossRef
17.
go back to reference ten Berg JM, Hutten BA, Kelder JC, et al. Oral anticoagulant therapy during and after coronary angioplasty: the intensity and duration of anticoagulation are essential to reduce thrombotic complications. Circulation 2001; 103: 2042–7PubMedCrossRef ten Berg JM, Hutten BA, Kelder JC, et al. Oral anticoagulant therapy during and after coronary angioplasty: the intensity and duration of anticoagulation are essential to reduce thrombotic complications. Circulation 2001; 103: 2042–7PubMedCrossRef
18.
go back to reference Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236–9PubMed Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236–9PubMed
19.
go back to reference Federation of Dutch Anticoagulation Clinics. Guideline for ambulatory treatment with cumarines [in Dutch]. Gravenhage: Federation of Dutch Anticoagulation Clinics, 2000 May Federation of Dutch Anticoagulation Clinics. Guideline for ambulatory treatment with cumarines [in Dutch]. Gravenhage: Federation of Dutch Anticoagulation Clinics, 2000 May
20.
go back to reference Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 1998; 114 Suppl.: 511S–23SPubMedCrossRef Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 1998; 114 Suppl.: 511S–23SPubMedCrossRef
21.
go back to reference Torn M, van der Meer FJ, Rosendaal FR. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med 2004; 164: 668–73PubMedCrossRef Torn M, van der Meer FJ, Rosendaal FR. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med 2004; 164: 668–73PubMedCrossRef
22.
go back to reference Penning-van Beest FJ, van Meegen E, Rosendaal FR, et al. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001; 86: 569–74PubMed Penning-van Beest FJ, van Meegen E, Rosendaal FR, et al. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001; 86: 569–74PubMed
23.
go back to reference Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98PubMedCrossRef Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98PubMedCrossRef
24.
go back to reference Penning-van Beest FJ, Geleijnse JM, van Meegen E, et al. Lifestyle and diet as risk factors for overanticoagulation. J Clin Epidemiol 2002; 55: 411–7PubMedCrossRef Penning-van Beest FJ, Geleijnse JM, van Meegen E, et al. Lifestyle and diet as risk factors for overanticoagulation. J Clin Epidemiol 2002; 55: 411–7PubMedCrossRef
25.
go back to reference Pasqualetti P, Moffa F, Chiovenda P, et al. Mini-mental state examination and mental deterioration battery: analysis of the relationship and clinical implications. J Am Geriatr Soc 2002; 50: 1577–81PubMedCrossRef Pasqualetti P, Moffa F, Chiovenda P, et al. Mini-mental state examination and mental deterioration battery: analysis of the relationship and clinical implications. J Am Geriatr Soc 2002; 50: 1577–81PubMedCrossRef
26.
go back to reference Tombaugh TN, Mclntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992; 40: 922–35PubMed Tombaugh TN, Mclntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992; 40: 922–35PubMed
27.
go back to reference Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care. Arch Intern Med 1998; 158: 1641–7PubMedCrossRef Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care. Arch Intern Med 1998; 158: 1641–7PubMedCrossRef
28.
go back to reference Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11–7PubMedCrossRef Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11–7PubMedCrossRef
29.
go back to reference Marder SR. Overview of partial compliance. J Clin Psychiatry 2003; 64Suppl. 16: 3–9PubMed Marder SR. Overview of partial compliance. J Clin Psychiatry 2003; 64Suppl. 16: 3–9PubMed
30.
go back to reference Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–310PubMedCrossRef Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–310PubMedCrossRef
31.
go back to reference van der Meer FJ, Briet E, Vandenbroucke JP, et al. The role of compliance as a cause of instability in oral anticoagulant therapy. Br J Haematol 1997; 98: 893–900PubMedCrossRef van der Meer FJ, Briet E, Vandenbroucke JP, et al. The role of compliance as a cause of instability in oral anticoagulant therapy. Br J Haematol 1997; 98: 893–900PubMedCrossRef
32.
go back to reference Salas M, In’t Veld BA, van der Linden PD, et al. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin Pharmacol Ther 2001; 70: 561–6PubMedCrossRef Salas M, In’t Veld BA, van der Linden PD, et al. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin Pharmacol Ther 2001; 70: 561–6PubMedCrossRef
33.
go back to reference Tang EO, Lai CS, Lee KK, et al. Relationship between patients’ warfarin knowledge and anticoagulation control. Ann Pharmacother 2003; 37: 34–9PubMedCrossRef Tang EO, Lai CS, Lee KK, et al. Relationship between patients’ warfarin knowledge and anticoagulation control. Ann Pharmacother 2003; 37: 34–9PubMedCrossRef
34.
go back to reference Kamath S, Lip GY. Atrial fibrillation in the elderly: anticoagulation strategies and indications in the very elderly. Am J Geriatr Cardiol 2002; 11: 357–62PubMedCrossRef Kamath S, Lip GY. Atrial fibrillation in the elderly: anticoagulation strategies and indications in the very elderly. Am J Geriatr Cardiol 2002; 11: 357–62PubMedCrossRef
35.
go back to reference Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997; 28: 2382–9PubMedCrossRef Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997; 28: 2382–9PubMedCrossRef
36.
go back to reference Gurwitz JH, Monette J, Rochon PA, et al. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997; 157: 978–84PubMedCrossRef Gurwitz JH, Monette J, Rochon PA, et al. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997; 157: 978–84PubMedCrossRef
Metadata
Title
Cognitive Impairment as Determinant for Sub-Optimal Control of Oral Anticoagulation Treatment in Elderly Patients with Atrial Fibrillation
Authors
Bob A. J. van Deelen
Dr Patricia M. L. A. van den Bemt
Toine C. G. Egberts
Annelies van’t Hoff
Huub A. A. M. Maas
Publication date
01-04-2005
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 4/2005
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200522040-00007

Other articles of this Issue 4/2005

Drugs & Aging 4/2005 Go to the issue

Therapy In Practice

Hypertension in the Elderly

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine